Cancer research

Dec 13, 2023

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transge...

Dec 13, 2023

Date of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-c...

Dec 13, 2023

Date of Abstract presentation10th December 2023IndicationsFollicular LymphomaAbstract Number3026Abstract typeOral According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Add...

Dec 12, 2023

Date of Abstract presentation9th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number1655Abstract typePoster Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, which is considered incurable and can be difficult to treat in the R/R setting. EPCORE NHL-1 is a multi-center tria...

Dec 12, 2023

Date of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose che...

Dec 11, 2023

Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and thi...

Dec 16, 2022

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

Nov 30, 2022

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...

Nov 25, 2022

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

Oct 27, 2022

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...